In a major breakthrough in the treatment of Alzheimer’s disease that may offer hope to millions of patients, the US Food and Drug Administration (FDA) has approved the first new Alzheimer’s drug in 20 years.
Everything you need to know about this hack is summed up in a Q&A: Read also What is the relationship between gum bacteria and Alzheimer’s disease? Mental fitness shield against Alzheimer’s Blood test detects Alzheimer’s 20 years before infection Is Alzheimer’s disease over? .. The invention of artificial nerve cells instead of the lost brain cells
What is the property?
The drug’s name is Aduhelm, and its scientific name is candelabrum .
How was it approved?
Adohlim has been approved by the US Food and Drug Administration under the Accelerated Approval pathway, under which the Food and Drug Administration approves a drug for a serious or life-threatening illness that may provide a meaningful therapeutic benefit over existing treatments, when it appears that the drug It has an effect that is reasonably likely to predict clinical benefit for patients and there remains some uncertainty about the clinical benefit of the drug, according to a statement on the administration’s website .
What is the importance of approval of the drug “Adohelm”?
According to the statement, this approval is important in many ways, including:
- Adohelm is the first approved new treatment for Alzheimer’s disease since 2003.
- ADOH is the first treatment directed at the underlying pathophysiology of Alzheimer’s disease, ie the presence of ‘amyloid beta plaques’ in the brain. The clinical trials of ADOHLM were the first to show that a reduction in plaques, a hallmark of the brain of Alzheimer’s patients, is expected to result in a reduction in the clinical worsening of this devastating form of dementia.
Who developed the drug Adolhelm?
The drug is developed by the American company “Biogen”.
How does adohelm work?
According to Dr. Patricia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research at the USCenters, in all the studies in which it was evaluated, Adohelm consistently and highly convincingly reduced the level of beta-amyloid plaques in the brain in a dose- and time-dependent manner.
A decrease in amyloid plaque would be expected to decrease clinical deterioration in patients.
What is the impact of this decline on Alzheimer’s patients?
Alzheimer’s usually affects people over the age of sixty years, and it begins in the form of mild symptoms such as forgetfulness and problems using language, but as it develops, the symptoms worsen, as the patient may no longer be able to identify his family members, or may face difficulties in speaking, reading and writing, He may also forget how to do simple, routine tasks like brushing teeth and combing his hair.
The disease begins with changes in the brain that begin a decade or more before the onset of symptoms, and abnormal clumps of a protein called beta-amyloid and fibers made up of “tau protein” begin to accumulate in the brain. With these abnormal accumulations and accumulations, the functions of neurons in the brain decline. https://imasdk.googleapis.com/js/core/bridge3.463.0_en.html#goog_109319072
Over time, the cells lose their ability to communicate and function, and eventually the cells die. As the dead cells increase, a person’s brain shrinks.
Therefore, the drug “Adohelm” by reducing the levels of beta-amyloid plaques, it reduces the progression of the disease and the deterioration of symptoms in the patient.
According to a report by Joseph Walker in the Wall Street Journal , the drug Addhelm is a lab-made antibody, and was designed based on antibodies taken from elderly people with very slow or no cognitive decline that scientists discovered to be special. with amyloid.
When injected into the body, Aduhelm antibodies attach to clumps of amyloid in the brain and remove it from the brain, although scientists aren’t quite sure how this happens. https://imasdk.googleapis.com/js/core/bridge3.463.0_en.html#goog_433751161
Are there limitations to the property?
The treatment may offer hope to the millions of people suffering from Alzheimer’s disease worldwide, however, the effect of Adolhelm may be limited, and doctors who say they will prescribe the drug warn that it will not help all patients, especially those with more advanced disease.
How much will it cost?
Biogen priced the newly approved drug higher than analysts had expected, and the company said it would charge about $56,000 annually to each patient.
Health insurer Cigna Corp estimates that some eligible patients may pay $10,000 or more annually, their share of the deductible under the health insurance policy.
What is Alzheimer’s?
One of the most common types of dementia, which usually affects adults, a disease that affects the brain and leads to a decline in a person’s ability to carry out his daily activities, and it begins slowly and includes the parts of the brain responsible for controlling thoughts, memory and language.
The disease took its name from the German doctor “Alois Alzheimer”, who described it in 1906, after he noticed anatomical changes in the brain of a woman who died of an unusual mental illness, and symptoms included memory loss and speech problems.
What are the risk factors for Alzheimer’s disease?
- Age. Most cases of Alzheimer’s occur at age 65 or older, and half of those aged 85 or older develop Alzheimer’s.
- Genes: Some people have rare genetic changes, and they develop Alzheimer’s in their forties or fifties, that is, at an early age.
- Having a first-degree relative with the disease, such as a father or brother.
- Women are more prone to Alzheimer’s than men, because they usually live longer.
- A person suffering from mild cognitive impairment may increase the risk of developing dementia and Alzheimer’s disease.
- Exposure to head trauma or injury.
- high cholesterol;
- Uncontrolled diabetes mellitus.
- Lack of social activities.
- Eat a diet low in vegetables and fruits.
On the other hand, there are factors that may reduce the risk of developing Alzheimer’s, such as:
- Have a high level of formal education.
- Frequent social interaction.
- Challenging mental activities such as reading, playing games and puzzles, or playing musical instruments.
- Forgetting, which includes appointments, events, or conversations.
- Repeating sentences and questions, as the person does not know that he has said this sentence or asked this question before.
- Difficulty recognizing the surroundings, which may lead the patient to get lost in places he was familiar with.
- Difficulties choosing words to pronounce and write.
- Thinking problems, such as the inability to manage and follow up on family financial accounts.
- Difficulty doing familiar things such as getting dressed and bathing.
- mood swings
- Delusions, such as the patient believing that something has been stolen.
- Changes in sleep pattern.